RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CStone Pharma of Suzhou has begun pivotal Phase II studies of its lead drug, a PD-L1 antibody, in two rare forms of lymphoma: natural killer cell/T-cell lymphoma and classical Hodgkin’s lymphoma. The two trials will test for efficacy and safety. According to CStone, CS1001 is China’s first fully human, full-length, IgG4 based anti-PD-L1 monoclonal antibody, an IO drug that was independently developed by CStone. The first patients have been dosed the two trials.
Source: China Biotoday
